Perspectives on market entry, commercial strategy, and the evolving India opportunity, from practitioners who execute, not just advise.
India's pharmaceutical market is the third largest by volume globally, yet most foreign entrants underestimate the complexity of local execution. We break down the five most common failure modes and what successful companies do differently.
Incentive structures, territory design, and field force management in India require a fundamentally different approach. Here's what 20 years of on-ground experience has taught us.
India's regulatory environment for pharma, biotech, and nutraceuticals is complex but navigable. We outline the key approval bodies, timelines, and common pitfalls for companies entering the market.
India's nutraceutical market is growing at 22% CAGR. We examine the category dynamics, distribution models, and brand-building strategies that are separating winners from the rest.
Each entry model carries different risk, capital, and speed-to-market trade-offs. We walk through the decision framework Provanta uses with global clients.
From Hyderabad's Genome Valley to Bengaluru's biotech corridor, India's biotech infrastructure has matured significantly. Here's where the real opportunities lie for foreign companies.
Global companies that localise their India supply chains gain a 15-30% cost advantage. We outline the strategic and operational steps to get there without sacrificing quality.
From demand forecasting to field force optimisation, AI is creating a new competitive divide in pharma. Here's how forward-looking companies in India and Africa are deploying it today.
Sub-Saharan Africa's pharmaceutical market is projected to reach $65 billion by 2030. We map the distribution infrastructure, regulatory frameworks, and partnership models that work.
Not all specialty ingredients are created equal. We break down what Indian pharma and nutraceutical manufacturers actually require from global suppliers, and where most fail to deliver.
India's price-sensitive market demands a fundamentally different pricing architecture. We explore tiered pricing, value-based models, and the NPPA framework that every foreign company must understand.
AI is not a strategy. It is an accelerant. We outline five concrete applications where generative AI is already delivering measurable ROI for pharma and biotech commercial teams.
Kenya, Ethiopia, and Tanzania are seeing rapid growth in consumer health and nutraceuticals. We examine the distribution infrastructure, regulatory landscape, and brand-building playbook.
India's fermentation industry is scaling rapidly, producing CoQ10, astaxanthin, and specialty amino acids at globally competitive prices. Here's what buyers need to know about quality and supply security.
The EU remains the most demanding but highest-value market for Indian pharma exporters. We outline the EMA approval pathway, GMP compliance requirements, and distribution models that work.
India is the world's largest biosimilar market by volume. We examine the competitive landscape, pricing dynamics, and partnership models available to global biotech companies.
FSSAI's evolving framework for health supplements and nutraceuticals is creating both compliance challenges and market opportunities. We break down the key changes and their commercial implications.
Hiring a full-time Chief Strategy Officer is not always the right move. We explain when the fractional CSO model delivers better outcomes, and what to look for in a fractional partner.
India's functional foods market is creating strong demand for high-purity omega-3 and algal DHA. We examine the supply landscape, quality benchmarks, and formulation considerations.
Nigeria, Ghana, and Ivory Coast represent a combined pharma market of over $4 billion. We map the distribution infrastructure, regulatory requirements, and partnership models that deliver results.
Real-time competitive intelligence, demand sensing, and regulatory monitoring are being transformed by AI. We share the tools and workflows that Provanta's consulting team uses with clients.
Get weekly insights on India's life sciences market, regulatory updates, and commercial strategy, directly from the field.
Strategy only creates value when it is executed. Let's discuss your India opportunity.
